Similar Search Results

Patents, Price Controls, and Access to New Drugs : How Policy Affects Global Market Entry

Lanjouw, Jean O. - 2005

Efforts to strengthen the global patent system for pharmaceuticals continue to be controversial, and what will likely …

Persistent link: https://www.econbiz.de/10012467362

Insurance Design and Pharmaceutical Innovation

Agha, Leila - 2020

This paper studies how insurance coverage policies affect incentives for pharmaceutical innovation. In the United …

Persistent link: https://www.econbiz.de/10012481418

Blockbusters, Sequels and the Nature of Innovation

Cohen, Wesley M.; Higgins, Matthew J.; Miles, William D.; … - National Bureau of Economic Research - 2025

segment and innovation choices, with implications for understanding the dynamics of technological change in R …

Persistent link: https://www.econbiz.de/10015421908

The Future of Drug Development : The Economics of Pharmacogenomics

Vernon, John A. - 2005

This paper models how the evolving field of pharmacogenomics (PG), which is the science of using genomic markers to predict drug response, may impact drug development times, attrition rates, costs, and the future returns to research and development (R&D). While there still remains an abundance...

Persistent link: https://www.econbiz.de/10012466796

The NBER Orange Book Dataset : A User's Guide

Durvasula, Maya; Hemphill, C. Scott; Ouellette, Lisa … - National Bureau of Economic Research - 2022

This paper introduces a newly digitized, open-access version of the Food and Drug Administration's "Orange Book"--a linkage between approved small-molecule drugs and the patents that protect them. The Orange Book also reports any applicable regulatory exclusivity that prevents competitive entry....

Persistent link: https://www.econbiz.de/10013462677

Improving Regulation for Innovation : Evidence from China's Pharmaceutical Industry

Jia, Ruixue; Ma, Xiao; Yang, Jianan; Zhang, Yiran - National Bureau of Economic Research - 2023

This study investigates how enhanced regulation can promote innovation, focusing on the impacts of a significant … recognized the improvement in drug innovation, as reflected in stock price adjustments post new drug registrations after the … latecomers could boost their innovation potential by adopting specific, effective regulatory practices from frontier countries …

Persistent link: https://www.econbiz.de/10014447297

Are Settlements in Patent Litigation Collusive? Evidence from Paragraph IV Challenges

Helland, Eric - 2016

should have expired, while proponents argue they reinforce incentives for innovation. We estimate the impact of settlements …

Persistent link: https://www.econbiz.de/10012456481

When Innovation Goes Wrong : Technological Regress and the Opioid Epidemic

Cutler, David M.; Glaeser, Edward L. - National Bureau of Economic Research - 2021

The fivefold increase in opioid deaths between 2000 and 2017 rivals even the COVID-19 pandemic as a health crisis for America. Why did it happen? Measures of demand for pain relief - physical pain and despair - are high but largely unchanging. The primary shift is in supply, primarily of new...

Persistent link: https://www.econbiz.de/10012533422

Investments in Pharmaceuticals Before and After TRIPS

Kyle, Margaret - 2009

We examine the relationship between patent protection for pharmaceuticals and investment in development of new drugs …

Persistent link: https://www.econbiz.de/10012463181

European Pharmaceutical Price Regulation, Firm Profitability, and R&D Spending

Golec, Joseph H. - 2006

EU countries closely regulate pharmaceutical prices whereas the U.S. does not. This paper shows how price constraints affect the profitability, stock returns, and R&D spending of EU and U.S. firms. Compared to EU firms, U.S. firms are more profitable, earn higher stock returns, and spend more on...

Persistent link: https://www.econbiz.de/10012465985